Various companies are working to develop therapies for the treatment of EBV+Cancers and PTLD. Key players such as Atara Biotherapeutics, Tessa Therapeutics, AlloVir are some of the major players that are going to boost the market dynamics in the coming years. The availability of these therapies may change the prescription patterns and the treatment scenario.
DelveInsight’s “Epstein Barr Virus (EBV) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Epstein Barr Virus market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Epstein Barr Virus market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Epstein Barr Virus (EBV): An Overview
Epstein–Barr virus (EBV), also known as human herpesvirus 4, is a member of the Herpesviridae family and is a ubiquitous pathogen that is persistently harbored by people throughout the world. EBV is the major cause of infectious mononucleosis (IM) and is associated with several malignancies, including nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma, Burkitt lymphoma, and lymphoma after the organ or stem cell transplant.
Primary infection with EBV is more frequent during childhood and causes mild disease, which most commonly happens through body fluids like saliva and persists as a latent infection in B-cells. The disease is typically asymptomatic in 20–80% of individuals by 2–3 years old. When uninfected teenagers and young adults are exposed to EBV, approximately 30–70% develop infectious mononucleosis (IM) and other EBV-associated diseases.
There are two types of EBV: type I and type II, also known as Types A and B. These two genotypes were distinguished based on the differences in the EBNA-2 gene. Epstein–Barr virus Type I and II can be subtracted into different EBV strains.
Epstein Barr Virus (EBV) Market Key Facts
The total number of Epstein–Barr Virus IM cases in the 7MM countries was more than 1,120,000 in 2021.
As per the estimates, the United States had the highest number of incident cases of Epstein–Barr Virus in 2021.
Among EU4 and the UK, Germany had the highest number of Epstein–Barr Virus cases, with more than 146,000 cases, followed by France in 2021.
Spain had the lowest number of Epstein–Barr Virus cases, with close to 79,000 cases in 202, among the Among EU4 and the UK.
EBV infection affects as many as 95% of American adults by age 35–40. Childhood EBV infection is indistinguishable from other transient childhood infections. Approximately 35-50% of adolescents and young adults who contract EBV infection have mononucleosis.
Epstein Barr Virus (EBV) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Epstein Barr Virus market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Epstein Barr Virus market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Epstein Barr Virus (EBV) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Epstein Barr Virus Epidemiology, Segmented as –
Total Diagnosed cases of EBV Infectious Mononucleosis [2019–2032]
Total Incident cases of EBV+ Cancers [2019–2032]
Total Incident cases of EBV+ PTLD [2019–2032]
Total Incident cases of EBV-associated tumors in the 7MM [2019–2032]
Epstein Barr Virus (EBV) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Epstein Barr Virus market or expected to be launched during the study period. The analysis covers the Epstein Barr Virus market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Epstein Barr Virus pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Epstein Barr Virus Market Will Evolve and Grow by 2032 @
The Leading Companies in the Epstein Barr virus (EBV) Therapeutics Market Include:
And Many More
Epstein–Barr Virus (EBV) Emerging and Marketed Drugs Covered in the Report Include:
FLX475: RAPT Therapeutics
Nanatinostat: Viracta Therapeutics
Posoleucel (ALVR105): Allovir
Tabelecleucel: Atara Biotherapeutics
TT10: Tessa Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Epstein Barr Virus Competitive Intelligence Analysis
4. Epstein Barr Virus Market Overview at a Glance
5. Epstein Barr Virus Disease Background and Overview
6. Epstein Barr Virus Patient Journey
7. Epstein Barr Virus Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Epstein Barr Virus Treatment Algorithm, Current Treatment, and Medical Practices
9. Epstein Barr Virus Unmet Needs
10. Key Endpoints of Epstein Barr Virus Treatment
11. Epstein Barr Virus Marketed Products
12. Epstein Barr Virus Emerging Drugs and Latest Therapeutic Advances
13. Epstein Barr Virus Seven Major Market Analysis
14. Attribute Analysis
15. Epstein Barr Virus Market Outlook (In US, EU5, and Japan)
16. Epstein Barr Virus Access and Reimbursement Overview
17. KOL Views on the Epstein Barr Virus Market
18. Epstein Barr Virus Market Drivers
19. Epstein Barr Virus Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your pharmaceutical portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Services
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States